IDEAYA Biosciences Gets FDA OK to Fast-Track Melanoma Treatment
December 05 2022 - 7:15AM
Dow Jones News
By Dean Seal
IDEAYA Biosciences Inc. said Monday that U.S. regulators granted
fast-track designation to its development program evaluating the
combination of two drugs for the treatment of metastatic uveal
melanoma.
The oncology company said the U.S. Food and Drug Administration
granted the designation for a program looking at darovasertib, a
potential first-in-class protein kinase C inhibitor, for use in
combination with crizotinib, an investigational cMET inhibitor.
The designation facilitates the development and expedites the
review of drugs that treat serious or life-threatening conditions
and fill unmet medical needs.
IDEAYA is currently targeting a potential registration-enabling
trial for the combination in the first quarter of 2023.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 05, 2022 07:00 ET (12:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
From Apr 2023 to Apr 2024